December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

54.83 -0.70 (-1.25%)
Delayed Quote Updated: 3:25 PM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
News headline image
Cracking The Code: Understanding Analyst Reviews For Genmab ↗
 
Via Benzinga
News headline image
What's Going On With Danish Healthcare Firm Genmab Stock? ↗
Genmab's legal update on Darzalex: Arbitrator dismisses bid for milestone payments. Despite this, diverse revenue sources, including royalty agreements, contribute to strong growth. 
Via Benzinga
News headline image
Investors seeking growth at a reasonable cost should explore NASDAQ:GMAB. ↗
NASDAQ:GMAB is showing good growth, while it is not too expensive. 
Via Chartmill
News headline image
9 Analysts Have This to Say About Genmab ↗
 
Via Benzinga
News headline image
NASDAQ:GMAB is not too expensive for the growth it is showing. ↗
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced. 
Via Chartmill
News headline image
Analyst Expectations for Genmab's Future ↗
 
Via Benzinga
News headline image
NASDAQ:GMAB, a strong growth stock, setting up for a breakout. ↗
GENMAB A/S -SP ADR (NASDAQ:GMAB)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
News headline image
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
News headline image
TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer
From Pfizer Inc.
Via Business Wire
News headline image
What 13 Analyst Ratings Have To Say About Genmab ↗
 
Via Benzinga
News headline image
Expert Ratings for Genmab ↗
 
Via Benzinga
News headline image
Analyst Expectations for Genmab's Future ↗
 
Via Benzinga
News headline image
NASDAQ:GMAB stands out as a growth opportunity that won't break the bank. ↗
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable. 
Via Chartmill
News headline image
Oracle Reports Weak Sales, Joins Kinetik, Lucid Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
U.S. stock futures were higher this morning, with the Dow Jones futures gaining over 50 points on Tuesday. 
Via Benzinga
Topics Stocks
News headline image
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
From Genmab A/S
Via Business Wire
News headline image
In the world of growth stocks, NASDAQ:GMAB shines as a value proposition. ↗
Investors seeking growth at a reasonable cost should explore GENMAB A/S -SP ADR (NASDAQ:GMAB). 
Via Chartmill
News headline image
Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
News headline image
7 Must-Buy Stocks That Are on Ridiculous Discount Now ↗
With Wall Street still chasing after the usual suspects in the tech ecosystem, astute investors may wish to target stocks on sale. 
Via InvestorPlace
News headline image
7 Underappreciated Biotech Stocks to Pick Up on the Cheap ↗
With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor. 
Via InvestorPlace
Topics Economy
News headline image
Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)
From Genmab A/S
Via Business Wire
News headline image
TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
From Seagen Inc.
Via Business Wire
News headline image
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable. ↗
While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable. 
Via Chartmill
News headline image
United Airlines, Interactive Brokers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
U.S. stock futures traded lower this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
News headline image
Don’t Miss the Boom: 3 Biotech Stocks Set to Explode Higher ↗
With their seamless blend of promise and innovation, these biotech stocks to buy offer a strategic gateway to fortify your portfolio. 
Via InvestorPlace
News headline image
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
News headline image
EPKINLY™ (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
From Genmab A/S
Via Business Wire
News headline image
Why Shares of Iovance Biotherapeutics Dropped Thursday ↗
The biotech stock's lead therapy is looking at some competition. 
Via The Motley Fool
News headline image
AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst ↗
On Sunday night, AstraZeneca Plc (NASDAQ: AZN) presented the Phase 3 FLAURA2 results evaluating Tagrisso plus chemotherapy versus Tagrisso monotherapy as first-line treatment for patients  
Via Benzinga
News headline image
Why Shares of Zai Lab Limited Were Jumping on Tuesday ↗
Zai Lab's shares benefited from positive clinical trial news. 
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.